Skip to main content

Randy Carpenter, MD

Chief Medical Officer
Rett Syndrome Research Trust
Randy Carpenter, MD
There is a great deal of excitement and anticipation surrounding gene replacement therapy in ...
Randy Carpenter, MD
The pace of scientific advance is rapidly enabling development of treatments targeting the core ...
Randy Carpenter, MD
As more and more therapeutic development programs advance from basic scientific research into ...
Randy Carpenter, MD
2019 started with the exciting announcement that our 2018 research awards totaled $10 million! ...
Randy Carpenter, MD
The entire Rett community celebrated on May 3 of this year when AveXis formally announced plans ...
Randy Carpenter, MD
A lot has happened in the six months since publication of our Gene Therapy Primer. Notably, two ...
Randy Carpenter, MD
It’s been an exciting several weeks for the field of RNA and DNA editing. Three days after ...
Randy Carpenter, MD
We are excited to report to the Rett Syndrome community and to everyone who cares about an ...
Randy Carpenter, MD
Background In the early 1980s, few drugs were being developed for rare diseases as the small ...
Randy Carpenter, MD
We live in exciting times. It seems like almost every day, breakthrough scientific discoveries ...
Randy Carpenter, MD
You -- the parents, grandparents, and families of children with Rett Syndrome -- know more than ...
Randy Carpenter, MD
Results from an RSRT funded clinical trial testing the drug copaxone (glatiramer acetate) in 10 ...
Randy Carpenter, MD
On July 11th we solicited questions on our blog for our Chief Scientific Officer, Randy ...
Randy Carpenter, MD
My first three months at RSRT have been a whirlwind of immersion in the Rett community. I’ve ...
Randy Carpenter, MD
Today is my first day at RSRT, and to say that I am excited would be an understatement. I have ...